Back to Search
ELAINE ATALLAH, M.D.
M.D.
Internal Medicine Physician
NPI: 1558352955Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
4301045091(MI)
Research & Publications (17)
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
PMID 19445582·Expert Rev Anticancer Ther·2009
6-review
Use of hypomethylating agents in myelodysplastic syndromes.
PMID 17679928·Clin Adv Hematol Oncol·2007
6-review
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
PMID 17673605·Blood·2007
8-other
Congestive heart failure is a rare event in patients receiving imatinib therapy.
PMID 17449798·Blood·2007
8-other
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
PMID 17382019·Clin Lymphoma Myeloma·2007
6-review
Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.
PMID 17255791·Curr Opin Hematol·2007
6-review
The role of decitabine in the treatment of myelodysplastic syndromes.
PMID 17163808·Expert Opin Pharmacother·2007
6-review
Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy.
PMID 12115389·Cancer·2002
5-case
Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
PMID 19654496·J Clin Rheumatol·2009
5-case
Practical considerations for the management of patients in the tyrosine kinase inhibitor era.
PMID 19621545·Semin Hematol·2009
8-other
Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.
PMID 19394693·Leuk Res·2009
5-case
Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
PMID 18059483·Leukemia·2008
8-other
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
PMID 17206119·Nat Med·2007
8-other
Agent Orange, prostate cancer irradiation and acute promyelocyic leukemia (APL): is there a link?
PMID 16956658·Leuk Res·2007
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 8550 N SILVERY LN, SUITE 200
DEARBORN HEIGHTS, MI 48127 - Phone
- (313) 561-2990
Quick Facts
- NPI
- 1558352955
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 17
Are you this provider?
Claim Your Profile